News & Updates

The addition of sotorasib to panitumumab significantly improves progression-free survival (PFS) in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (CRC) compared with the investigator’s choice of standard-of-care (SoC) treatment, according to the CodeBreaK 300 trial presented at ESMO Asia 2023.

Treatment with tiotropium appears to reduce the risk of clinically important deterioration (CID) in patients with mild-to-moderate chronic obstructive pulmonary disease (COPD), including those with fewer respiratory symptoms, according to a study.

Sacituzumab govitecan improved progression-free survival (PFS) and overall survival (OS) in Asian patients with HR+/HER2– metastatic breast cancer (mBC) compared with the treatment of physician’s choice (TPC*), according to the EVER-132-002 study presented at ESMO Asia 2023.

Among people with hearing loss, those who use their hearing aids regularly appear to live longer than those who do not use the device, according to a study.

The risk of osteoporotic fracture seems greater in patients with autoimmune hepatitis (AIH), reveals a recent study. In addition, those with cirrhosis and long-term use of glucocorticoids appear to be at much greater risk.

It is safe to use long-term growth hormone (GH) therapy in patients with decompensated cirrhosis (DC), suggests a study, noting improvements in malnutrition and even quality of life (QoL). However, 12-month survival does not seem to improve.

A recent study has shown that among individuals with chronic hyponatremia, its correction leads to improved cognitive function as well as decreased brain volume and neuronal activity.